Literature DB >> 31401266

RNAi therapeutic strategies for acute respiratory distress syndrome.

Melissa L Jagrosse1, David A Dean2, Arshad Rahman2, Bradley L Nilsson3.   

Abstract

Acute respiratory distress syndrome (ARDS), replacing the clinical term acute lung injury, involves serious pathophysiological lung changes that arise from a variety of pulmonary and nonpulmonary injuries and currently has no pharmacological therapeutics. RNA interference (RNAi) has the potential to generate therapeutic effects that would increase patient survival rates from this condition. It is the purpose of this review to discuss potential targets in treating ARDS with RNAi strategies, as well as to outline the challenges of oligonucleotide delivery to the lung and tactics to circumvent these delivery barriers.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2019        PMID： 31401266      PMCID： PMC7316156          DOI： 10.1016/j.trsl.2019.07.011

Source DB:  PubMed          Journal:  Transl Res        ISSN： 1878-1810            Impact factor:   7.012


  243 in total

Review 1.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue.

Authors:  Jayanth Panyam; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2003-02-24       Impact factor: 15.470

2.  TNF-alpha increases tyrosine phosphorylation of vascular endothelial cadherin and opens the paracellular pathway through fyn activation in human lung endothelia.

Authors:  Daniel J Angelini; Sang-Won Hyun; Dmitry N Grigoryev; Pallavi Garg; Ping Gong; Ishwar S Singh; Antonino Passaniti; Jeffery D Hasday; Simeon E Goldblum
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-08-04       Impact factor: 5.464

3.  Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers.

Authors:  Dave Singh; Steven M Fox; Ruth Tal-Singer; Jonathan Plumb; Stewart Bates; Peter Broad; John H Riley; Bartolome Celli
Journal:  Thorax       Date:  2011-03-24       Impact factor: 9.139

Review 4.  Acute lung injury and cell death: how many ways can cells die?

Authors:  Peter S Tang; Marco Mura; Rashmi Seth; Mingyao Liu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-01-18       Impact factor: 5.464

5.  Albuterol delivery in a model of mechanical ventilation. Comparison of metered-dose inhaler and nebulizer efficiency.

Authors:  P Diot; L Morra; G C Smaldone
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

6.  Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

Authors:  Richard B Moss; David Rodman; L Terry Spencer; Moira L Aitken; Pamela L Zeitlin; David Waltz; Carlos Milla; Alan S Brody; John P Clancy; Bonnie Ramsey; Nicole Hamblett; Alison E Heald
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

7.  Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial.

Authors:  Robert W Taylor; Janice L Zimmerman; R Phillip Dellinger; Richard C Straube; Gerard J Criner; Kenneth Davis; Kathleen M Kelly; Thomas C Smith; Robert J Small
Journal:  JAMA       Date:  2004-04-07       Impact factor: 56.272

Review 8.  Peptides used in the delivery of small noncoding RNA.

Authors:  Ravi S Shukla; Bin Qin; Kun Cheng
Journal:  Mol Pharm       Date:  2014-09-08       Impact factor: 4.939

9.  Ribosomal Protein S3 Gene Silencing Protects Against Cigarette Smoke-Induced Acute Lung Injury.

Authors:  Jinrui Dong; Wupeng Liao; Hong Yong Peh; W S Daniel Tan; Shuo Zhou; W S Fred Wong
Journal:  Mol Ther Nucleic Acids       Date:  2018-07-03       Impact factor: 8.886

10.  RNAi Therapeutic Platforms for Lung Diseases.

Authors:  Yu Fujita; Fumitaka Takeshita; Kazuyoshi Kuwano; Takahiro Ochiya
Journal:  Pharmaceuticals (Basel)       Date:  2013-02-06
View more
  5 in total

Review 1.  Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome.

Authors:  Makhloufi Zoulikha; Qingqing Xiao; George Frimpong Boafo; Marwa A Sallam; Zhongjian Chen; Wei He
Journal:  Acta Pharm Sin B       Date:  2021-08-12       Impact factor: 11.413

Review 2.  Gene Therapy for Acute Respiratory Distress Syndrome.

Authors:  Jing Liu; David A Dean
Journal:  Front Physiol       Date:  2022-01-17       Impact factor: 4.566

Review 3.  Nanomedicine-Based Therapeutics to Combat Acute Lung Injury.

Authors:  Youbin Cui; Wanguo Liu; Shuai Bian; Hongfei Cai; Chunsheng Xiao
Journal:  Int J Nanomedicine       Date:  2021-03-18

4.  Nanoscale Porphyrin Metal-Organic Frameworks Deliver siRNA for Alleviating Early Pulmonary Fibrosis in Acute Lung Injury.

Authors:  Changmei Weng; Guanhua Li; Dongdong Zhang; Zhaoxia Duan; Kuijun Chen; Jieyuan Zhang; Tao Li; Jianmin Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-07-18

5.  Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody.

Authors:  Hector Quijada; Tadeo Bermudez; Carrie L Kempf; Daniel G Valera; Alexander N Garcia; Sara M Camp; Jin H Song; Evelyn Franco; Jessica K Burt; Belinda Sun; Joseph B Mascarenhas; Kimberlie Burns; Amir Gaber; Radu C Oita; Vivian Reyes Hernon; Christy Barber; Liliana Moreno-Vinasco; Xiaoguang Sun; Anne E Cress; Diego Martin; Zhonglin Liu; Ankit A Desai; Viswanathan Natarajan; Jeffrey R Jacobson; Steven M Dudek; Christian Bime; Saad Sammani; Joe G N Garcia
Journal:  Eur Respir J       Date:  2021-05-06       Impact factor: 33.795
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.